C. Purpose of this Guidance, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

  • To outline the practical arrangements for notification.
  • To provide advice on what should and what should not be classified as a “serious breach” and what must be reported.
  • To outline possible actions that may be taken by the MHRA in response to notifications of serious breaches.

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

Protecting the Heart Before Going Home: Hospitals Test Giving Flu Shots Right Before Discharge
High Cholesterol: New Non-Statin Drug to Be Compared Directly With Bempedoic Acid
Delivering Radiation Straight to the Tumor: New Prostate Cancer Trial Begins
Stroke Care Beyond 4.5 Hours: Trial Tests Simpler CT Screening
Huntington’s Disease: Scientists to Re-Test a Drug Aimed at Preserving Memory and Movement
Blisters, Fever, and Lost Appetite: New Vaccine Against Hand, Foot, and Mouth Disease to Be Tested on 6,000 Children
Helping Your Gut on GLP-1: Can a Daily Fiber Supplement Boost Metabolism During Weight Loss?

Připravované klinické studie

Clinical Research Jobs

More jobs

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

Předplatit